Beat Foerster1,2, Carmen Pozo1,3, Mohammad Abufaraj1,4, Andrea Mari1, Shoji Kimura1,5, David D'Andrea1, Hubert John2, Shahrokh F Shariat1,6,7,8. 1. Department of Urology, Medical University of Vienna, Vienna, Austria. 2. Department of Urology, Kantonsspital Winterthur, Winterthur, Switzerland. 3. Department of Urology, Hospital Universitario Fundación Alcorcón, Madrid, Spain. 4. Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan. 5. Department of Urology, Jikei University School of Medicine, Tokyo, Japan. 6. Department of Urology, Weill Cornell Medical College, New York, New York. 7. Department of Urology, University of Texas Southwestern Medical Center, Dallas. 8. Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria.
Abstract
Importance: Studies investigating the association of cigarette smoking with prostate cancer incidence and outcomes have revealed controversial results. Objective: To systematically review and analyze the association of smoking status with biochemical recurrence, metastasis, and cancer-specific mortality among patients with localized prostate cancer undergoing primary radical prostatectomy or radiotherapy. Data Sources: A systematic search of original articles published between January 2000 and March 2017 was performed using PubMed, MEDLINE, Embase, and Cochrane Library databases in March 2017. Study Selection: Observational studies reporting Cox proportional hazards regression or logistic regression analyses were independently screened. Data Extraction and Synthesis: This systematic review and meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement and the Cochrane Handbook for Systematic Reviews of Interventions. Available multivariable hazard ratios (HRs) and corresponding 95% CIs were included in quantitative analysis. A risk-of-bias assessment was completed for nonrandomized studies. Main Outcomes and Measures: Prespecified outcomes of interest were biochemical recurrence, metastasis, and cancer-specific mortality. Results: A total of 5157 reports were identified, of which 16 articles were selected for qualitative analysis and 11 articles were selected for quantitative analysis. All included studies were observational and nonrandomized and comprised a total of 22 549 patients. Overall, 4202 patients (18.6%) were current smokers. The overall median follow-up was 72 months. Current smokers had a statistically significantly higher risk of biochemical recurrence (HR, 1.40; 95% CI, 1.18-1.66; P < .001 [10 studies]), as did former smokers (HR, 1.19; 95% CI, 1.09-1.30; P < .001 [7 studies]). Current smokers were also at a higher risk of metastasis (HR, 2.51; 95% CI, 1.80-3.51; P < .001 [3 studies]) and cancer-specific mortality (HR, 1.89; 95% CI, 1.37-2.60; P < .001 [5 studies]), whereas former smokers were not (metastasis: HR, 1.61; 95% CI, 0.65-3.97; P = .31 [2 studies]; cancer-specific mortality: HR, 1.05; 95% CI, 0.81-1.37; P = .70 [4 studies]). Conclusions and Relevance: Current smokers at the time of primary curative treatment for localized prostate cancer are at higher risk of experiencing biochemical recurrence, metastasis, and cancer-specific mortality.
Importance: Studies investigating the association of cigarette smoking with prostate cancer incidence and outcomes have revealed controversial results. Objective: To systematically review and analyze the association of smoking status with biochemical recurrence, metastasis, and cancer-specific mortality among patients with localized prostate cancer undergoing primary radical prostatectomy or radiotherapy. Data Sources: A systematic search of original articles published between January 2000 and March 2017 was performed using PubMed, MEDLINE, Embase, and Cochrane Library databases in March 2017. Study Selection: Observational studies reporting Cox proportional hazards regression or logistic regression analyses were independently screened. Data Extraction and Synthesis: This systematic review and meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement and the Cochrane Handbook for Systematic Reviews of Interventions. Available multivariable hazard ratios (HRs) and corresponding 95% CIs were included in quantitative analysis. A risk-of-bias assessment was completed for nonrandomized studies. Main Outcomes and Measures: Prespecified outcomes of interest were biochemical recurrence, metastasis, and cancer-specific mortality. Results: A total of 5157 reports were identified, of which 16 articles were selected for qualitative analysis and 11 articles were selected for quantitative analysis. All included studies were observational and nonrandomized and comprised a total of 22 549 patients. Overall, 4202 patients (18.6%) were current smokers. The overall median follow-up was 72 months. Current smokers had a statistically significantly higher risk of biochemical recurrence (HR, 1.40; 95% CI, 1.18-1.66; P < .001 [10 studies]), as did former smokers (HR, 1.19; 95% CI, 1.09-1.30; P < .001 [7 studies]). Current smokers were also at a higher risk of metastasis (HR, 2.51; 95% CI, 1.80-3.51; P < .001 [3 studies]) and cancer-specific mortality (HR, 1.89; 95% CI, 1.37-2.60; P < .001 [5 studies]), whereas former smokers were not (metastasis: HR, 1.61; 95% CI, 0.65-3.97; P = .31 [2 studies]; cancer-specific mortality: HR, 1.05; 95% CI, 0.81-1.37; P = .70 [4 studies]). Conclusions and Relevance: Current smokers at the time of primary curative treatment for localized prostate cancer are at higher risk of experiencing biochemical recurrence, metastasis, and cancer-specific mortality.
Authors: Harun Fajkovic; Shahrokh F Shariat; Tobias Klatte; Mihai Dorin Vartolomei; Ilaria Lucca; Aurélie Mbeutcha; Morgan Rouprêt; Alberto Briganti; Pierre I Karakiewicz; Vitaly Margulis; Michael Rink; Mesut Remzi; Christian Seitz; Karim Bensalah; Romain Mathieu Journal: World J Urol Date: 2016-02-15 Impact factor: 4.226
Authors: J Lee Westmaas; Christina C Newton; Victoria L Stevens; W Dana Flanders; Susan M Gapstur; Eric J Jacobs Journal: J Clin Oncol Date: 2015-04-20 Impact factor: 44.544
Authors: Michael Rink; Emily C Zabor; Helena Furberg; Evanguelos Xylinas; Behfar Ehdaie; Giacomo Novara; Marko Babjuk; Armin Pycha; Yair Lotan; Quoc-Dien Trinh; Felix K Chun; Richard K Lee; Pierre I Karakiewicz; Margit Fisch; Brian D Robinson; Douglas S Scherr; Shahrokh F Shariat Journal: Eur Urol Date: 2012-11-27 Impact factor: 20.096
Authors: Zhihong Gong; Ilir Agalliu; Daniel W Lin; Janet L Stanford; Alan R Kristal Journal: Cancer Causes Control Date: 2007-09-30 Impact factor: 2.506
Authors: Jacqueline M Major; Hillary S Klonoff-Cohen; John P Pierce; Donald J Slymen; Sidney L Saltzstein; Caroline A Macera; Dan Mercola; Michael W Kattan Journal: PLoS One Date: 2011-02-24 Impact factor: 3.240
Authors: Jeremy Tey; Yu Yang Soon; Timothy Cheo; Kiat Huat Ooi; Francis Ho; Balamurugan Vellayappan; David Chia; Bee Choo Tai Journal: In Vivo Date: 2019 Nov-Dec Impact factor: 2.155
Authors: Paul Riviere; Abhishek Kumar; Elaine Luterstein; Lucas K Vitzthum; Vinit Nalawade; Reith R Sarkar; Alex K Bryant; John P Einck; Arno J Mundt; James D Murphy; Brent S Rose Journal: Prostate Cancer Prostatic Dis Date: 2019-10-17 Impact factor: 5.554
Authors: Karly A Murphy; Elizabeth M Stone; Rachel Presskreischer; Emma E McGinty; Gail L Daumit; Craig E Pollack Journal: Med Care Date: 2021-04-01 Impact factor: 3.178